Why XRTX rose 21.1% on Oct 9 2026: planned clinical trial application
XRTX+21.1%on Fri Oct 9 2026
XORTX Therapeutics Inc. Common Stock was up 21.1% on the day at $2.24, ranked #9 on 2453× its usual five-minute volume, when TapeRank recorded this spike at 07:53 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 07:53 ETMOVER · PRE-MARKET
$2.24 · ▲ 21.1% ON THE DAY · 2453× 5M RVOL · RANK #9
STRETCHEDCONFIDENCE5/5XRTX is up 10.8% pre-market after announcing plans to prepare a Health Canada clinical trial application for its XORLO gout program. The filing is a development milestone, not approval or clinical data, and the additional commercialization-partner inquiries are unquantified.
WHYA planned CTA and unquantified partner interest are modest catalysts relative to a 10.8% pre-market move on 55x typical volume and a 1.8M-share float.ANALYZED 07:45 ET · 8 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 07:53 ET
LAST2.24DAY▲ 21.1%5 MIN▲ 3.23%5M RVOL2453×5M $VOL$3.5MFLOAT*1.8MRANK#9SESSIONPRE-MARKETVWAP2.09HOD2.23LOD1.83OR HIGH—OR LOW—PREV CLOSE1.85PM HIGH2.23PM LOW1.83GAP▲ 16.76% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $2.05, +10.8% on the previous close of $1.85
- 09:30 ETRegular-session high, $2.08
- 14:00 ETRegular-session low, $1.36
- 15:59 ETLast trade of the regular session, $1.42, -23.2% on the previous close of $1.85
- Volume: 4.7M shares in regular hours, 12.3M before the open
XRTX opened at $2.05 after rising to $2.24 premarket, following news that XORTX planned to prepare a Health Canada clinical trial application for its XORLO gout program ahead of a planned FDA filing; TapeRank read the development milestone and unquantified commercialization-partner inquiries as a modest catalyst relative to the premarket move. The stock reached $2.08 at the open, then declined to a $1.36 low by 14:00 ET before ending at $1.42, with no halts. TapeRank’s read tied the early move to the planned clinical trial application, not approval or clinical data.
WRITTEN THU OCT 15 2026 18:04 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 02:50 ETXORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's WhyBenzinga
- THU 16:07 ET6-K — Foreign issuer reportSEC 6-K
- THU 16:01 ETXORTX Therapeutics Plans Health Canada Clinical Trial Application For Gout Drug XORLO Ahead Of Planned FDA FilingBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list